

Sepsis Update Advisory Committee Interests Register

Register last updated: 09 January 2024

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|-----------------|-------------------------------|--|---|----------------|-------------------|-----------------|--|
| Ann Hoskins | Chair | Direct non-financial professional and personal interests | Advocate / member of the British Association of Child and Adolescent PH. | | Dec-2021 | Ongoing | Declare and participate. Rationale: Not specific to the update of the guideline |
| Ann Hoskins | Chair | Direct non-financial professional and personal interests | Board Member, Plus Dane Housing Association | 2016 | May 2022 | Ongoing | Declare and participate. Rationale: Not specific to the update of the guideline |
| Ann Hoskins | Chair | Direct financial | Independent Public Health Consultant | Apr-16 | May-22 | Ongoing | Declare and participate Rationale: Self-employed providing NHS services. |
| Samina Begum | Lay member | Nil | Nil | Nil | Nil | Nil | Nil |
| Louise Bradbury | Consultant Nurse for Outreach | Direct financial | Critical Care Outreach and Deteriorating Patient Lead, Watford General Teaching Hospital | Jan-21 | Oct-22 | Ongoing | Declare and participate Rationale: Salaried employment in the NHS. |
| Tumena Corrah | Consultant in Acute Medicine | Non-financial professional and personal | Arberry J, Henry Z, Corrah T. A simple measure to improve sepsis documentation and coding. Clin Med (Lond) 2021; 21(3):222-225. | 2021 | May-22 | | Declare and participate Rationale: Not specific to the scope of the guideline |

| | | | | | | | |
|-----------------|----------------------------------|---|--|------------|------------|------------|---|
| Tumena Corrah | Consultant in Acute Medicine | Non-financial professional and personal | Enoch DA, Cargill JS, Laing R, Herbert S, Corrah TW , Brown NM. Value of CT-guided biopsy in the diagnosis of septic discitis. J Clin Pathol 2008; 61(6):750-753. | | | | Declare and participate Rationale: Not specific to the scope of the guideline |
| Tumena Corrah | Consultant in Acute Medicine | Direct financial | Consultant in infectious Diseases and Acute Medicine and Honorary Senior Clinical Lecturer (Imperial College London) | Apr-15 | Oct-22 | Ongoing | Declare and participate Rationale: Salaried employment at educational institution. |
| Savio Fernandes | Consultant Haemoncologist | Direct financial | Consultant in Haematology, Didley Group NHS Foundation Trust | April-04 | Oct-22 | Ongoing | Declare and participate Rationale: Salaried employment in the NHS. |
| Savio Fernandes | Consultant Haemoncologist | Direct financial | Payment for contribution to a journal article/case report series on Gilteritinib in the management of Acute Myeloid Leukaemia | March 2023 | April 2023 | March 2023 | Declare and participate. Rationale: Not specific to the scope of the guideline. |
| Peter Gosling | Lay Member | Nil | Nil | Nil | Nil | Nil | Nil |
| Alasdair Gray | Consultant in Emergency Medicine | Non-financial professional and personal | Co-Chief Investigator. Feasibility of 5% Albumin compared with Balanced crystalloid, intravenous fluid resuscitation in adult Sepsis patients presenting as an emergency to hospital: The ABC Sepsis Trial. Finished recruitment, in follow up. Feasibility trial | 2020 | May-22 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline |

| | | | | | | | |
|---------------|----------------------------------|---|--|-------------|-------------|---------|---|
| Alasdair Gray | Consultant in Emergency Medicine | Non-financial professional and personal | Co-investigator. Vasopressors in Sepsis (EVIS). NIHR HTA programme (NIHR132594); (2021-2026). Pragmatic trial of low dose early vasopressor compared with current standard of care in patients with sepsis presenting to UK EDs. Trial currently in set up. | 2021 | May-22 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline |
| Alasdair Gray | Consultant in Emergency Medicine | Direct financial | Consultant in Emergency Medicine, NHS Lothian and Honorary Professor, University of Edinburgh | 2021 | May-22 | Ongoing | Declare and participate Rationale: Salaried employment in the NHS. |
| Alasdair Gray | Consultant in Emergency Medicine | Indirect financial | Co-applicant on an NIHR platform trial on biomarkers and prognosis for patients presenting to emergency care with presumed infection. Currently at stage 1 review with HTA (Jan-24) | December-24 | December-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of this update. Will be reviewed at the next stage. |
| Alasdair Gray | Consultant in Emergency Medicine | Indirect financial | Consultancy work for MeMed. Part of their expert panel to determine where their host/biomarker (which helps decide on viral/bacterial infection) fits within the NHS pathway. Fee for this work is to be paid to NHS Lothian. | January-24 | Dec-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of this update. Will be reviewed at the next stage. |

| | | | | | | | |
|----------------|--------------------------------------|---|--|----------|--------|---------|--|
| Jeremy Henning | Consultant in Critical Care Medicine | Direct financial | Consultant Intensive Care Medicine, South Tees NHS Foundation Trust | April-02 | May-22 | Ongoing | Declare and participate Rationale: salaried employment in the NHS. |
| Erum Khan | Consultant Obstetrician | Non-financial professional and personal | RCOG Patient Safety Committee member | May-22 | May-22 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline |
| Erum Khan | Consultant Obstetrician | Direct financial | Consultant Obstetrician and Gynaecologist, Milton Keynes University Hospital | Apr-15 | Oct-22 | Ongoing | Declare and participate Rationale: Salaried employment in the NHS. |
| Tessa Lewis | General Practitioner | Direct financial | Chair of the NICE Management of Common Infections Committee | | May-22 | Oct22 | Declare and participate Rationale: Not specific to the scope of the guideline |
| Tessa Lewis | General Practitioner | Direct financial | Chair of the NICE UTI in under 16s update committee | Oct-21 | May-22 | July-22 | Declare and participate Rationale: Not specific to the scope of the guideline |
| Tessa Lewis | General Practitioner | Non-financial professional and personal | Guest speaker on The Aural Apothecary podcast | 2021 | May-21 | May-21 | Declare and participate Rationale: Not specific to the scope of the guideline |
| Tessa Lewis | General Practitioner | Non-financial professional and personal | Developed webinar & slide set on decision points for remote management of common infections. Topics included otitis media, sinusitis, cough and other common infections - Included within paid role as medical | Dec-21 | Oct-21 | | Declare and participate Rationale: Not specific to the scope of the guideline |

| | | | | | | | |
|--------------------|----------------------|---|---|--------|--------|---------|---|
| | | | adviser to PHE primary care intervention unit/ TARGET toolkit | | | | |
| Tessa Lewis | General Practitioner | Non-financial professional and personal | Chair of the NICE Pneumonia update committee | Jul-22 | Sep-22 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline |
| Tessa Lewis | General Practitioner | Direct financial | General practitioner (locum) with special interest in frailty | Aug-21 | May-22 | Ongoing | Declare and participate |
| Tessa Lewis | General Practitioner | Non-financial professional and personal | Royal College of General Practitioners representative on UKHSA ESPAUR | Oct-22 | Apr-23 | Ongoing | Declare and participate. Rationale: A survey of anti-microbial resistance but not specific to sepsis. |
| Tessa Lewis | General Practitioner | Non-financial professional and personal | Royal College of General Practitioners representative on UK Standards for Microbiology Investigations steering committee. | Apr-23 | Apr-23 | Ongoing | Declare and participate. Agreed by: Guideline Lead Rationale: Not specifically looking at Sepsis so not specific to the scope of the guideline. |
| Barry Murphy-Jones | Paramedic | Non-financial professional and personal | Murphy-Jones, B. & Shaw, J. (2016). Level of Sepsis Knowledge In UK Ambulance Services. <i>Emergency Medical Journal</i> , 33: e10-e11. | 2016 | May-22 | Nil | Declare and participate Rationale: Not specific to the scope of the guideline |
| Barry Murphy-Jones | Paramedic | Direct financial | Senior Lecturer – Paramedic Science, University of Hertfordshire | Jan-22 | Oct-22 | Ongoing | Declare and participate |

| | | | | | | | |
|--------------------|--------------------------------------|---|--|---------|---------|---------|--|
| | | | | | | | Rationale: Salaried employment in higher education. |
| Barry Murphy-Jones | Paramedic | Direct financial | Associate Lecturer, Angela Ruskin University | Nov-19 | Oct-22 | Ongoing | Declare and participate Rationale: Salaried employment in higher education. |
| Barry Murphy-Jones | Paramedic | Direct financial | Advanced Paramedic Practitioner – Critical Care, London Ambulance Service | Sep-17 | Oct-22 | Ongoing | Declare and participate Rationale: Salaried employment in the NHS. |
| Barry Murphy-Jones | Paramedic | Non-financial professional and personal | ERC young Masterclass – potential peer reviewer for Resuscitation Plus | Sept-23 | Sept-23 | July-24 | Declare and participate Not specific to the scope of the guideline |
| Marlies Ostermann | Consultant in Critical Care Medicine | Direct financial | Speaker honoraria from Fresenius Medical Care, Baxter and Biomerieux (payment was used to support research studies) | Jan-20 | May-22 | Mar-22 | Declare and participate Rationale: Not specific to the scope of the guideline |
| Marlies Ostermann | Consultant in Critical Care Medicine | Indirect financial | Research funding from Fresenius Medical Care, Baxter, Biomerieux and LaJolla Pharma (funding was awarded to institution) | Jan-19 | May-22 | Feb-22 | Declare and participate Rationale: Not specific to the scope of the guideline |
| Marlies Ostermann | Consultant in Critical Care Medicine | Direct financial | Member of advisory committee for Mission Therapeutics and Pfizer | Jan-21 | May-22 | Feb-22 | Declare and participate Rationale: Not specific to the scope of the guideline |

| | | | | | | | |
|-------------------|--------------------------------------|---|---|-----------|--------|---------|--|
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Deputy Co-Chair of Surviving Sepsis Guidelines Committee | 2019 | May-22 | 2021 | Declare and participate Rationale: Interest is specific and open declaration is sufficient mitigation. Interest will be kept under review depending on the matter under consideration. |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Member of Surviving Sepsis Research Committee | July 2021 | May-22 | Ongoing | Declare and participate Rationale: Interest is specific and open declaration is sufficient mitigation. Interest will be kept under review depending on the matter under consideration. |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Principal investigator of REVIVAL trial (RCT comparing the role of recombinant alkaline phosphatase in critically ill patients with sepsis and acute kidney injury) | 2021 | May-22 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Principal Investigator of CLASSIC trial (RCT comparing restrictive versus liberal fluid management in patients with septic shock) | 2020 | May-22 | 2022 | Declare and participate Rationale: Not specific to the scope of the guideline |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Principal investigator of ATHOS III trial (RCT investigating the role of | 2015 | May-22 | 2017 | Declare and participate Rationale: Not specific to the scope of the guideline |

| | | | | | | | |
|-------------------|--------------------------------------|---|---|------|--------|---------|--|
| | | | Angiotensin II in vasodilatory shock) | | | | |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Director of Research, Chair of Standards Committee and Council member of Intensive Care Society UK | 2020 | May-22 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Chair of Research Committee of European Society of Intensive Care Medicine and Member of Executive Committee | 2021 | May-22 | Oct-22 | Declare and participate Rationale: Interest is specific and open declaration is sufficient mitigation. Interest will be kept under review depending on the matter under consideration. |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Member of AKI!Now Committee of the American Society of Nephrology | 2020 | May-22 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Coordinator of European Sepsis Survey | 2020 | May-22 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Member of Royal Society of Medicine Critical Care Council | 2020 | May-22 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Spoden M et al. Occurrence and risk factors for new dependency on chronic care, respiratory support, dialysis and mortality in the first year after sepsis. | 2022 | May-22 | | Declare and participate Rationale: Not specific to the scope of the guideline |

| | | | | | | | |
|-------------------|--------------------------------------|---|--|------|--------|--|---|
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Bakker J et al. Current practice and evolving concepts in septic shock resuscitation. Intensive Care Med 2021;48:148-163 | 2021 | May-22 | | <p>Declare and participate</p> <p>Rationale: Interest is specific and open declaration is sufficient mitigation.</p> <p>Interest will be kept under review depending on the matter under consideration.</p> |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Evans L et al. Executive Summary: Surviving Sepsis Campaign: International Guidelines for the Management Sepsis and Septic Shock 2021. Crit Care Med 2021;49(11):1971-1982 | 2021 | May-22 | | <p>Declare and participate</p> <p>Rationale: Interest is specific and open declaration is sufficient mitigation.</p> <p>Interest will be kept under review depending on the matter under consideration.</p> |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Evans L et al. Surviving sepsis campaign: international guidelines for the management of sepsis and septic shock. Intensive Care Med 2021;47(11):1181-1247 | 2021 | May-22 | | <p>Declare and participate</p> <p>Rationale: Interest is specific and open declaration is sufficient mitigation.</p> <p>Interest will be kept under review depending on the matter under consideration.</p> |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | De Backer D et al. Challenges in the management of septic shock: a narrative review. Intensive Care Med 2019;Feb 11 | 2019 | May-22 | | <p>Declare and participate</p> <p>Rationale: Interest is specific and open declaration is sufficient mitigation.</p> <p>Interest will be kept under review depending on the matter under consideration.</p> |

| | | | | | | | |
|-------------------|---|---|--|----------|---------|---------|--|
| Marlies Ostermann | Consultant in Critical Care Medicine | Direct financial | Consultant in Critical Care & Nephrology, Guy's and St. Thomas Hospital | Nov-05 | May-22 | Ongoing | Declare and participate Rationale: Salaried employment in the NHS. |
| Marlies Ostermann | Consultant in Critical Care Medicine | Non-financial professional and personal | Honorary Senior Lecturer, King's College London | Dec-09 | May-22 | Sept 21 | Declare and participate Rationale: Non-salaried employment in educational services. |
| Marlies Ostermann | Consultant in Critical Care Medicine | Direct financial | Professor in Intensive Care Medicine, King's College London | Sep-21 | May-22 | Ongoing | Declare and participate Rationale: Salaried employment in educational services. |
| Giovanni Satta | Consultant Microbiologist/Infectious Disease Specialist | Direct financial | Consultant in Infection (Microbiology and Infectious Diseases) and Infection Control Doctor, University College London Hospitals | Feb-21 | Oct-22 | Ongoing | Declare and participate Rationale: Salaried employment at educational institution. |
| Giovanni Satta | Consultant Microbiologist/Infectious Disease Specialist | Direct financial | Associate Professor, University College London Hospitals | Feb-21 | Oct-22 | Ongoing | Declare and participate Rationale: Salaried employment in educational services. |
| Mervyn Singer | Topic Adviser | Direct financial | Professor of Intensive Care Medicine and Director, Centre for Intensive Care Medicine, Division of Medicine, University College London | Oct-2001 | June-23 | Ongoing | Declare and participate Rationale: Salaried employment at educational institution. |
| Mervyn Singer | Topic Adviser | Direct financial | Advisory board member, Enlivex - Israeli company | Dec-19 | June-23 | Ongoing | Declare and participate |

| | | | | | | | |
|---------------|---------------|------------------|--|---------|---------|---------|---|
| | | | developing a novel cell-based therapy for sepsis | | | | Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Direct financial | Advisory board member, deepUII – Spanish company developing a molecular diagnostic for pathogens (transcriptomic technology) which they are planning to combine with a Raman spectroscopic approach for rapid assessment of antibiotic susceptibility. | Apr-21 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Direct financial | Advisory board member, Safeguard Biosystems – US company developing a molecular diagnostic for pathogens (transcriptomic technology) | Dec-21 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Direct financial | Advisory board member, Aptarion - Swiss company developing a novel drug for sepsis | May-22 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Direct financial | Advisory board member, Roche Diagnostics – multinational company developing novel pathogen diagnostics | Nov-22 | June-23 | Feb-23 | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Direct financial | Advisory board member, Matisse Pharmaceuticals – | Sept-23 | June-23 | Ongoing | Declare and participate |

| | | | | | | | |
|---------------|---------------|---|---|------|---------|----------|--|
| | | | Dutch company developing a novel drug for sepsis | | | | Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Non-financial professional and personal | Council member (and past-Chair) International Sepsis Forum – group of sepsis experts who organize a yearly international sepsis meeting, colloquia, and provide advice to Industry | 2009 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Non-financial professional and personal | Member, Acute Deterioration Board, NHS England | 2021 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline |
| Mervyn Singer | Topic Adviser | Non-financial professional and personal | Vice-Chair, Academy of Medical Royal Colleges Working Group on initial antibiotic treatment for sepsis | 2019 | June-23 | 2023 | Declare and participate |
| Mervyn Singer | Topic Adviser | Non-financial professional and personal | Trustee for the University College London Hospitals NHS Foundation Trust (UCLH) Charity. The role involved giving input into how money was invested and spent (applications for internal hospital grants, quality improvement projects, patient experience enhancements etc.) | 2017 | June-23 | March-23 | Declare and participate Rationale: Interest is specific and open declaration is sufficient mitigation. Interest will be kept under review depending on the matter under consideration. |
| Mervyn Singer | Topic Adviser | Non-financial professional and personal | Multiple peer-reviewed publications on the use of fluids, antibiotics and | 1990 | June-23 | Ongoing | Declare and participate |

| | | | | | | | |
|---------------|---------------|---|---|------|---------|---------|--|
| | | | vasoactive agents, novel diagnostics and novel drugs and technologies for management of sepsis | | | | Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Non-financial professional and personal | Co-investigator on current NIHR-funded multi-centre trials on sepsis management – (i) ADAPT-Sepsis (Award 15/99/02) and SepTIC (Award 17/136/02) | 2015 | June-23 | Ongoing | Declare and participate Rationale: Interest is specific and open declaration is sufficient mitigation. Interest will be kept under review depending on the matter under consideration. |
| Mervyn Singer | Topic Adviser | Non-financial professional and personal | UCL Technology Fund Award to develop novel in-house therapy for sepsis | 2021 | June-23 | 2023 | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Non-financial professional and personal | Principal clinical investigator (in conjunction with Oxford Optronix) - Wellcome Trust/Dept Health Award to develop novel monitor for monitoring organ perfusion adequacy | 2016 | June-23 | 2023 | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Non-financial professional and personal | Pre-symptom Health – unpaid advisor to Ministry of Defence (DSTL) spin-off company developing novel sepsis diagnostic test | 2019 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |

| | | | | | | | |
|---------------|---------------|---|--|------|---------|---------|---|
| Mervyn Singer | Topic Adviser | Non-financial professional and personal | Clinical studies performed on the UCLH intensive care unit on novel sepsis and pathogen diagnostics - Gentian, Biomerieux | 2019 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Direct financial | Rosetrees Trust Award – preclinical studies to enhance activity of existing antibiotics by incorporation into cationic liposomes and addition of DNA nanotubes | 2021 | June-23 | 2023 | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Indirect financial | Deltex Medical – UK company making haemodynamic monitoring device- royalties and advisory board honorarium paid into my Research Fund held by UCLH Charity. I have sole control over these funds along with an intensive care colleague. | 2000 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Indirect financial | Biotest – German company producing immunoglobulin therapy for sepsis - advisory board - honorarium paid into my Research Fund held by UCL. I have sole control over these funds along with an intensive care colleague. | 2016 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Indirect financial | Biomerieux – French company developing novel pathogen diagnostics - advisory board and | 2019 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |

| | | | | | | | |
|---------------|---------------|--------------------|---|---------|---------|---------|--|
| | | | educational videos - honorarium paid into my Research Fund held by UCL. I have sole control over these funds along with an intensive care colleague. | | | | |
| Mervyn Singer | Topic Adviser | Indirect financial | Fresenius - German company producing intravenous fluids – chair of satellite meeting, speaker at educational meeting - honorarium paid into my Research Fund held by UCL. I have sole control over these funds along with an intensive care colleague. | June-23 | June-23 | Oct-23 | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Indirect financial | Hemotune – Swiss company developing extracorporeal therapy for sepsis - advisory board - honorarium paid into my Research Fund held by UCL. I have sole control over these funds along with an intensive care colleague. | Sept-21 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Indirect financial | NewB - Hong Kong-based company developing new therapy for ischaemia- reperfusion injury - chair of DSMC honorarium paid into my Research Fund held by UCL. I have sole control over these funds along with an intensive care colleague. | Oct-18 | June-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline update |

| | | | | | | | |
|---------------|---------------|--------------------|--|--------|---------|--------|---|
| Mervyn Singer | Topic Adviser | Indirect financial | Pfizer – multinational company and manufacturer of novel antibiotic - speaking at satellite meeting - honorarium paid into my Research Fund held by UCLH Charity. I have sole control over these funds along with an intensive care colleague. | Mar-23 | June-23 | Mar-23 | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Indirect financial | Pfizer - multinational company and manufacturer of novel antibiotic - advisory Board - honorarium paid into my Research Fund held by UCLH Charity. I have sole control over these funds along with an intensive care colleague. | Nov-22 | June-23 | Nov-22 | Declare and participate Rationale: Not specific to the scope of the guideline update |
| Mervyn Singer | Topic Adviser | Indirect financial | ProMISe (funded by NIHR HTA Programme) Co-funding applicant and contributor - Protocolized Management in Sepsis (ProMISe): A multi-centre, randomized controlled trial of the clinical and cost-effectiveness of early goal-directed protocolized resuscitation for emerging septic shock. https://pubmed.ncbi.nlm.nih.gov/26597979/ | Nov-19 | Dec-23 | | Declare and participate Rationale: Not specific to the scope of this update. To be reviewed for the next stage where it is in scope. |

| | | | | | | | |
|---------------|---------------|--------------------|---|--------|--------|---------|---|
| Mervyn Singer | Topic Adviser | Indirect financial | NIHR Efficacy and Mechanism Evaluation Programme Award 15/99/02 Co-funding applicant and contributor - Biomarker-guided Duration of Antibiotic treatment in hospitalised Patients with moderate to severe Sepsis. The ADAPT-Sepsis Trial. https://journals.sagepub.com/doi/full/10.1177/17511437231169193 | Apr-23 | Dec-23 | | Declare and participate Rationale: Not specific to the scope of this update. To be reviewed for the next stage where it is in scope. |
| Mervyn Singer | Topic Adviser | Indirect financial | NIHR Efficacy and Mechanism Evaluation Programme Award Co-funding applicant and contributor - Study into the Reversal of Septic Shock with Landiolol (STRESS-L) https://pubmed.ncbi.nlm.nih.gov/33593781/ | Feb-21 | Dec-23 | | Declare and participate Rationale: Not specific to the scope of this update. To be reviewed for the next stage where it is in scope. |
| Mervyn Singer | Topic Adviser | Indirect financial | NIHR Research Award 17/136/02 Co-funding applicant and contributor - Sepsis Trials in Critical Care (SepTIC) https://fundingawards.nihr.ac.uk/award/17/136/02 | May-22 | Dec-23 | Ongoing | Declare and participate Rationale: Not specific to the scope of this update. To be reviewed for the next stage where it is in scope. |

| | | | | | | | |
|---------------|---------------|--------------------|--|--------|--------|--------|---|
| Mervyn Singer | Topic Adviser | Indirect financial | EU DLV-676129 Marie Curie Innovative Training Network Award [€546,576] European Sepsis Academy: towards new biomarkers to improve sepsis management (Principal Investigator at UCL) | Mar-16 | Dec-23 | Feb-20 | Declare and participate Rationale: Not specific to the scope of this update. To be reviewed for the next stage where it is in scope. |
| Mervyn Singer | Topic Adviser | Indirect financial | Innovate UK Biomedical Catalyst Early Stage Award to Mologic Ltd 82371-510474 [£1,255,191] Principal Clinical Investigator Sepsis Alert Test | 2017 | Dec-23 | 2019 | Declare and participate Rationale: Not specific to the scope of this update. To be reviewed for the next stage where it is in scope. |
| Mervyn Singer | Topic Adviser | Indirect financial | MRC Research Award (MR/T025441/1) [£841,264] Reeder JB, Singer M. Co-funding applicant and contributor - Optimisation of the manufacture of a homogeneous synthetic hemoglobin as a novel Oxygen Therapeutic / Blood Substitute | Nov-20 | Dec-23 | Jul-23 | Declare and participate Rationale: Not specific to the scope of this update. To be reviewed for the next stage where it is in scope. |
| Mervyn Singer | Topic Adviser | Indirect financial | UCL Technology Fund Award (UTF-21-006) [£150,000] Singer M, Kleyman A, Press A, Bauer M. Principal funding applicant - Development of a phytosterol therapy for | 2022 | Dec-23 | 2023 | Declare and participate Rationale: Not specific to the scope of this update. To be reviewed for the next stage where it is in scope. |

| | | | | | | | |
|------------|--|---|--|--------|--------|--------|--|
| | | | sepsis-induced myocardial depression | | | | |
| Sally Wood | Consultant Nurse in Emergency Medicine | Indirect financial | Successful grant from Pfizer to appoint a colleague in a secondment role at NUH for 12months leading on blood culture improvement project. | Oct-21 | May-22 | Apr-23 | Declare and participate Rationale: Not specific to the scope of the guideline |
| Sally Wood | Consultant Nurse in Emergency Medicine | Non-financial professional and personal | “Predicting 30-day mortality in patients with sepsis; an exploratory analysis of process or care and patient characteristics” (2018) <i>The journal of Intensive Care Society</i> . Sanderson, M., Moppett, I., Chikhani, M., Simmonds, M., Wood, S., McKeever, T. | 2018 | May-22 | | Declare and participate Rationale: Not specific to the scope of the guideline |
| Sally Wood | Consultant Nurse in Emergency Medicine | Non-financial professional and personal | “Improving outcome of sepsis on the ward: introducing the sepsis six bundle” Burke, J., Wood, S., Hermon, A., Szakmany, T., Jan 2019 <i>Nursing in Critical Care BACCN</i> . 24 (1) | Jan-19 | May-22 | | Declare and participate Rationale: Interest is specific and open declaration is sufficient mitigation. Interest will be kept under review depending on the matter under consideration. |
| Sally Wood | Consultant Nurse in Emergency Medicine | Non-financial professional and personal | “Surviving sepsis beyond intensive care: survival rates at one decade.” Dec 2018. Patel, R., Wood, S.D., Ford, A., Hutchinson, A., Weston, V., Simmonds, M., Chikhani, M. <i>Intensive care State of the art 2018 Conference</i> | Dec-18 | May-22 | | Declare and participate Rationale: Not specific to the scope of the guideline |

| | | | | | | | |
|------------|--|---|---|--------|--------|---------|---|
| Sally Wood | Consultant Nurse in Emergency Medicine | Non-financial professional and personal | "Sepsis Bags: Simple method to increase procedure compliance with sepsis six on the ward" (2013) Burke, J., Smith, L., Wood, S., Hermon, A., Szakmany, T. <i>Poster presentation at ESICM Annual Congress, Paris: LIVES 2013.</i> | 2013 | May-22 | | Declare and participate Rationale: Not specific to the scope of the guideline |
| Sally Wood | Consultant Nurse in Emergency Medicine | Direct financial | Recognise and Rescue and Sepsis Matron, Nottingham University Hospitals NHS Trust | 2019 | Oct-22 | Ongoing | Declare and participate Rationale: Salaried employment in the NHS. |
| Sally Wood | Consultant Nurse in Emergency Medicine | Non-financial professional and personal | Member of the UK Sepsis Practitioner Forum | Oct-22 | Oct-22 | Ongoing | Declare and participate Rationale: Not specific to the scope of the guideline. |

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.